Astellas Pharma Stock Net Income
| ALPMF Stock | USD 16.33 0.28 1.74% |
As of the 12th of February 2026, Astellas Pharma shows the Downside Deviation of 5.1, mean deviation of 1.85, and Risk Adjusted Performance of 0.1784. Astellas Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Astellas Pharma variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Astellas Pharma is priced correctly, providing market reflects its regular price of 16.33 per share. Given that Astellas Pharma has jensen alpha of 0.6654, we suggest you to validate Astellas Pharma's prevailing market performance to make sure the company can sustain itself at a future point.
Astellas Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Astellas Pharma's valuation are provided below:Astellas Pharma does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Astellas |
Astellas Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Astellas Pharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Astellas Pharma.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Astellas Pharma on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Astellas Pharma or generate 0.0% return on investment in Astellas Pharma over 90 days. Astellas Pharma is related to or competes with Grifols SA, Orion Oyj, Genmab A/S, WuXi Biologics, Fresenius Medical, WuXi Biologics, and BioMérieux. Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide More
Astellas Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Astellas Pharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Astellas Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.1 | |||
| Information Ratio | 0.1811 | |||
| Maximum Drawdown | 15.86 | |||
| Value At Risk | (4.30) | |||
| Potential Upside | 5.88 |
Astellas Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Astellas Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Astellas Pharma's standard deviation. In reality, there are many statistical measures that can use Astellas Pharma historical prices to predict the future Astellas Pharma's volatility.| Risk Adjusted Performance | 0.1784 | |||
| Jensen Alpha | 0.6654 | |||
| Total Risk Alpha | 0.2824 | |||
| Sortino Ratio | 0.1061 | |||
| Treynor Ratio | (1.90) |
Astellas Pharma February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1784 | |||
| Market Risk Adjusted Performance | (1.89) | |||
| Mean Deviation | 1.85 | |||
| Semi Deviation | 1.97 | |||
| Downside Deviation | 5.1 | |||
| Coefficient Of Variation | 463.48 | |||
| Standard Deviation | 2.99 | |||
| Variance | 8.92 | |||
| Information Ratio | 0.1811 | |||
| Jensen Alpha | 0.6654 | |||
| Total Risk Alpha | 0.2824 | |||
| Sortino Ratio | 0.1061 | |||
| Treynor Ratio | (1.90) | |||
| Maximum Drawdown | 15.86 | |||
| Value At Risk | (4.30) | |||
| Potential Upside | 5.88 | |||
| Downside Variance | 25.99 | |||
| Semi Variance | 3.87 | |||
| Expected Short fall | (3.52) | |||
| Skewness | (0.13) | |||
| Kurtosis | 3.86 |
Astellas Pharma Backtested Returns
Astellas Pharma appears to be somewhat reliable, given 3 months investment horizon. Astellas Pharma secures Sharpe Ratio (or Efficiency) of 0.18, which signifies that the company had a 0.18 % return per unit of risk over the last 3 months. By analyzing Astellas Pharma's technical indicators, you can evaluate if the expected return of 0.53% is justified by implied risk. Please makes use of Astellas Pharma's Risk Adjusted Performance of 0.1784, downside deviation of 5.1, and Mean Deviation of 1.85 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Astellas Pharma holds a performance score of 13. The firm shows a Beta (market volatility) of -0.33, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Astellas Pharma are expected to decrease at a much lower rate. During the bear market, Astellas Pharma is likely to outperform the market. Please check Astellas Pharma's semi variance, and the relationship between the maximum drawdown and daily balance of power , to make a quick decision on whether Astellas Pharma's price patterns will revert.
Auto-correlation | 0.67 |
Good predictability
Astellas Pharma has good predictability. Overlapping area represents the amount of predictability between Astellas Pharma time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Astellas Pharma price movement. The serial correlation of 0.67 indicates that around 67.0% of current Astellas Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.67 | |
| Spearman Rank Test | 0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 0.63 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Astellas Pharma reported net income of 124.09 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The net income for all United States stocks is significantly lower than that of the firm.
Astellas Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Astellas Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Astellas Pharma could also be used in its relative valuation, which is a method of valuing Astellas Pharma by comparing valuation metrics of similar companies.Astellas Pharma is currently under evaluation in net income category among its peers.
Astellas Fundamentals
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 26.19 B | |||
| Shares Outstanding | 1.83 B | |||
| Shares Owned By Insiders | 0.37 % | |||
| Shares Owned By Institutions | 50.43 % | |||
| Price To Earning | 25.09 X | |||
| Price To Book | 2.38 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 1.3 T | |||
| Gross Profit | 1.04 T | |||
| EBITDA | 241.52 B | |||
| Net Income | 124.09 B | |||
| Cash And Equivalents | 336.76 B | |||
| Cash Per Share | 184.77 X | |||
| Total Debt | 4.87 B | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 1.34 X | |||
| Book Value Per Share | 861.58 X | |||
| Cash Flow From Operations | 257.44 B | |||
| Earnings Per Share | 0.57 X | |||
| Target Price | 50.0 | |||
| Number Of Employees | 14.52 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 26.66 B | |||
| Total Asset | 2.33 T | |||
| Retained Earnings | 941.23 B | |||
| Working Capital | 491.17 B | |||
| Current Asset | 874.69 B | |||
| Current Liabilities | 383.53 B | |||
| Z Score | 3.0 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 2.25 % | |||
| Net Asset | 2.33 T | |||
| Last Dividend Paid | 25.0 |
About Astellas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Astellas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astellas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astellas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Astellas Pink Sheet
Astellas Pharma financial ratios help investors to determine whether Astellas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.